Please login to the form below

aducanumab

This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Another amyloid-targeting treatment, Biogen’s aducanumab, is currently being reviewed by the US Food and Drug Administration (FDA). ... However, due to the lack of new treatments for Alzheimer’s emerging in the last decade, it may still approve

Latest news

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

Aside from MS, Biogen has high hopes for its potential Alzheimer’s disease therapy aducanumab, which is currently under review with the US Food and Drug Administration. ... However, as no new Alzheimer’s disease therapies have been approved in over a
Novo Nordisk launches late-stage study in Alzheimer’s disease

One of the most promising potential treatments of late to come through the development pipeline for Alzheimer’s is Biogen’s aducanumab, which is currently under review with the US Food
Biogen signs $3.1bn deal with Sage for potential depression therapies

The deal bolsters Biogen’s pipeline as it awaits a key FDA decision on its potential Alzheimer’s disease treatment aducanumab. ... The agency is set to announce its final decision on whether to approve aducanumab’s Biologics Licence Application (BLA
FDA advisory committee overwhelmingly votes no on Biogen's aducanumab

In the EMERGE study, patients who received the highest dose of aducanumab demonstrated a statistically significant improvement on a clinical dementia scale. ... Aside from the two phase 3 studies, Biogen also submitted data from a phase 1b trial –
FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Briefing documents published by the US Food and Drug Administration (FDA) before an advisory committee meeting on Friday have initially backed Biogen’s potential Alzheimer’s treatment aducanumab. ... years. The field of Alzheimer’s research has

More from news
Approximately 15 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Alzheimer’s: the search for a cure

The preponderance of the data indicates aducanumab doesn’t provide a clinical benefit,’ Skorney wrote in a note to investors. ... If, after receiving input from an advisory committee, the FDA decides to approve aducanumab, it will provide an
Great expectations: the urgent need for common purpose in Alzheimer’s disease

Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
Detecting Alzheimer’s ahead of a cure

Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate.
Where next in Alzheimer’s disease R&D?

Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab
The good, the bad and the ugly

Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Account Director: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Senior Account Manager: Competitive

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...